14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CFRX ranks #17062 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

ContraFect Corporation Stock Forecast NASDAQ:CFRX

$2.86 (-9.49%)

Volume: 350k

Closed: Dec 03, 2021

Hollow Logo Score: -6.780

ContraFect Corporation Stock Forecast

$2.86 (-9.49%)

Volume: 350k

Closed: Dec 03, 2021

Score Hollow Logo -6.780
Which way will CFRX go? Request
Key Stats
Beta 1.36
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The ContraFect Corporation stock currently holds an RSI14 at 23 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

High volatility in ContraFect Corporation stock price on Friday which ended trading at $2.86
(Updated on Dec 03, 2021)


Sell candidate since 2021-11-26 Loss -18.75%

The ContraFect Corporation stock price fell by -9.49% on the last day (Friday, 3rd Dec 2021) from $3.16 to $2.86. During the day the stock fluctuated 12.50% from a day low at $2.80 to a day high of $3.15. The price has risen in 6 of the last 10 days, but is still down by -13.07% for this period. Volume has increased on the last day by 130 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 350 thousand shares were bought and sold for approximately $1.00 million.

Given the current short-term trend, the stock is expected to fall -14.68% during the next 3 months and, with a 90% probability hold a price between $2.44 and $3.22 at the end of this 3-month period.

Signals & Forecast

There are few to no technical positive signals at the moment. The ContraFect Corporation stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $3.24 and $3.67. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, September 27, 2021, and so far it has fallen -33.18%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). ContraFect Corporation gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.35 between high and low, or 12.50%. For the last week, the stock has had a daily average volatility of 14.06%.

ContraFect Corporation is oversold on RSI14 (23). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is ContraFect Corporation stock A Buy?

ContraFect Corporation holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -6.780

Predicted Opening Price for ContraFect Corporation of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$2.94 $2.86 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 16, 2021 "Mizuho" gave "$10.00 - $9.00" rating for CFRX. The price target was changed from $3.67 to 2.7%.

Volatility and Risk
Daily Average Volatility: 14.06 %
Overall Risk: Very High High Medium Low Very Low
Volatility
14.06 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $3.08
Price: $2.86
No Support Found

CFRX Insider Trading Show all Trades

INSIDER POWER

1.181

Last 87 transactions
Buy: 1 608 209 | Sell: 1 361 184 (Shares)
Date Action Amount Person Type
May 18, 2021 Buy 25 000 Sucoff Cary Options (Right to Buy)
May 18, 2021 Buy 25 000 Barer Sol J Options (Right to Buy)
May 18, 2021 Buy 25 000 Low David N. Options (Right to Buy)
May 18, 2021 Buy 25 000 Aklog Lishan Options (Right to Buy)
May 18, 2021 Buy 25 000 Otto Michael J. Options (Right to Buy)
Show all Insider Trades
INSIDER POWER

1.181

Last 87 transactions
Buy: 1 608 209 | Sell: 1 361 184 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 3.29 14.92 %
3.15 10.24 %
3.07 7.36 %
Current price: 2.86
Support 2.80 -1.99 %
2.72 -4.88 %
2.59 -9.56 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 3.48 21.68 %
3.41 19.23 %
3.08 7.69 %
Current price 2.86
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About ContraFect Corporation

ContraFect ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT